Antenatal and intrapartum nucleic acid amplification test use for group B Streptococcus screening—United States, 2016
Diagnostic Microbiology and Infectious Disease
© 2018 Elsevier Inc. Perinatal group B Streptococcus (GBS) disease prevention guidelines in 2010 allowed for processing of screening specimens by nucleic acid amplification tests (NAATs); however, the extent of NAAT use is unknown. A 2016 laboratory survey sent to 10 surveillance sites found that 18.7% of responding laboratories offered NAAT for GBS screening (antenatal only: 7.3%; intrapartum only: 4.1%; both: 3.4%).
Fay, Katherine; Almendares, Olivia; Robinson-Dunn, Barbara; and Schrag, Stephanie, "Antenatal and intrapartum nucleic acid amplification test use for group B Streptococcus screening—United States, 2016" (2019). Articles. 58.